These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31182618)

  • 1. Intradermal Synthetic DNA Vaccination Generates
    Louis L; Clark M; Wise MC; Glennie N; Wong A; Broderick K; Uzonna J; Weiner DB; Scott P
    Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31182618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of DNA vaccination against cutaneous leishmaniasis.
    Méndez S; Belkaid Y; Seder RA; Sacks D
    Vaccine; 2002 Nov; 20(31-32):3702-8. PubMed ID: 12399198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
    Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
    Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.
    Bayih AG; Daifalla NS; Gedamu L
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3391. PubMed ID: 25500571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S; Ghaemimanesh F; Zahedifard F
    Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
    Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
    Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.
    López-Fuertes L; Pérez-Jiménez E; Vila-Coro AJ; Sack F; Moreno S; Konig SA; Junghans C; Wittig B; Timón M; Esteban M
    Vaccine; 2002 Dec; 21(3-4):247-57. PubMed ID: 12450700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection.
    Coelho EA; Tavares CA; Lima Kde M; Silva CL; Rodrigues JM; Fernandes AP
    Parasitol Res; 2006 May; 98(6):568-75. PubMed ID: 16432754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
    J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.
    Gicheru MM; Olobo JO; Anjili CO; Orago AS; Modabber F; Scott P
    Infect Immun; 2001 Jan; 69(1):245-51. PubMed ID: 11119512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
    Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
    Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
    Bolhassani A; Gholami E; Zahedifard F; Moradin N; Parsi P; Doustdari F; Seyed N; Papadopoulou B; Rafati S
    Exp Parasitol; 2011 May; 128(1):9-17. PubMed ID: 21276444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.